vs
Grand Canyon Education, Inc.（LOPE）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Grand Canyon Education, Inc.的季度营收约是Ultragenyx Pharmaceutical Inc.的1.5倍（$308.1M vs $207.3M），Grand Canyon Education, Inc.净利率更高（28.1% vs -62.0%，领先90.2%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 5.3%），Grand Canyon Education, Inc.自由现金流更多（$122.9M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 5.9%）
大峡谷教育（Grand Canyon Education, Inc.）是美国的营利性上市企业，核心业务为高等院校提供课程开发、在线教育解决方案及运营支持服务。该公司最初与亚利桑那州的基督教院校大峡谷大学关联，2008年分拆为独立实体上市。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
LOPE vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $308.1M | $207.3M |
| 净利润 | $86.7M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | 35.1% | -54.7% |
| 净利率 | 28.1% | -62.0% |
| 营收同比 | 5.3% | 25.9% |
| 净利润同比 | 5.9% | 3.5% |
| 每股收益（稀释后） | $3.13 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $308.1M | $207.3M | ||
| Q3 25 | $261.1M | $159.9M | ||
| Q2 25 | $247.5M | $166.5M | ||
| Q1 25 | $289.3M | $139.3M | ||
| Q4 24 | $292.6M | $164.6M | ||
| Q3 24 | $238.3M | $139.5M | ||
| Q2 24 | $227.5M | $147.0M | ||
| Q1 24 | $274.7M | $108.8M |
| Q4 25 | $86.7M | $-128.6M | ||
| Q3 25 | $16.3M | $-180.4M | ||
| Q2 25 | $41.5M | $-115.0M | ||
| Q1 25 | $71.6M | $-151.1M | ||
| Q4 24 | $81.9M | $-133.2M | ||
| Q3 24 | $41.5M | $-133.5M | ||
| Q2 24 | $34.9M | $-131.6M | ||
| Q1 24 | $68.0M | $-170.7M |
| Q4 25 | 35.1% | -54.7% | ||
| Q3 25 | 6.9% | -106.9% | ||
| Q2 25 | 20.9% | -64.8% | ||
| Q1 25 | 30.4% | -102.6% | ||
| Q4 24 | 34.2% | -74.3% | ||
| Q3 24 | 20.2% | -94.6% | ||
| Q2 24 | 18.8% | -79.1% | ||
| Q1 24 | 30.8% | -151.9% |
| Q4 25 | 28.1% | -62.0% | ||
| Q3 25 | 6.2% | -112.8% | ||
| Q2 25 | 16.8% | -69.0% | ||
| Q1 25 | 24.8% | -108.5% | ||
| Q4 24 | 28.0% | -80.9% | ||
| Q3 24 | 17.4% | -95.7% | ||
| Q2 24 | 15.3% | -89.5% | ||
| Q1 24 | 24.8% | -156.8% |
| Q4 25 | $3.13 | $-1.28 | ||
| Q3 25 | $0.58 | $-1.81 | ||
| Q2 25 | $1.48 | $-1.17 | ||
| Q1 25 | $2.52 | $-1.57 | ||
| Q4 24 | $2.83 | $-1.34 | ||
| Q3 24 | $1.42 | $-1.40 | ||
| Q2 24 | $1.19 | $-1.52 | ||
| Q1 24 | $2.29 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $111.8M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $746.9M | $-80.0M |
| 总资产 | $992.3M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $111.8M | $421.0M | ||
| Q3 25 | $97.3M | $202.5M | ||
| Q2 25 | $192.3M | $176.3M | ||
| Q1 25 | $144.5M | $127.1M | ||
| Q4 24 | $324.6M | $174.0M | ||
| Q3 24 | $263.6M | $150.6M | ||
| Q2 24 | $241.3M | $480.7M | ||
| Q1 24 | $196.2M | $112.3M |
| Q4 25 | $746.9M | $-80.0M | ||
| Q3 25 | $758.0M | $9.2M | ||
| Q2 25 | $778.0M | $151.3M | ||
| Q1 25 | $780.7M | $144.2M | ||
| Q4 24 | $783.9M | $255.0M | ||
| Q3 24 | $764.1M | $346.8M | ||
| Q2 24 | $759.2M | $432.4M | ||
| Q1 24 | $759.4M | $140.3M |
| Q4 25 | $992.3M | $1.5B | ||
| Q3 25 | $1.0B | $1.2B | ||
| Q2 25 | $1.0B | $1.3B | ||
| Q1 25 | $1.0B | $1.3B | ||
| Q4 24 | $1.0B | $1.5B | ||
| Q3 24 | $992.9M | $1.5B | ||
| Q2 24 | $992.7M | $1.6B | ||
| Q1 24 | $1.0B | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $130.5M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $122.9M | $-100.8M |
| 自由现金流率自由现金流/营收 | 39.9% | -48.6% |
| 资本支出强度资本支出/营收 | 2.5% | 0.5% |
| 现金转化率经营现金流/净利润 | 1.50× | — |
| 过去12个月自由现金流最近4个季度 | $238.6M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $130.5M | $-99.8M | ||
| Q3 25 | $-48.6M | $-91.4M | ||
| Q2 25 | $124.0M | $-108.3M | ||
| Q1 25 | $67.6M | $-166.5M | ||
| Q4 24 | $135.8M | $-79.3M | ||
| Q3 24 | $-29.4M | $-67.0M | ||
| Q2 24 | $98.6M | $-77.0M | ||
| Q1 24 | $85.0M | $-190.7M |
| Q4 25 | $122.9M | $-100.8M | ||
| Q3 25 | $-58.3M | $-92.7M | ||
| Q2 25 | $115.4M | $-110.7M | ||
| Q1 25 | $58.7M | $-167.8M | ||
| Q4 24 | $126.1M | $-79.5M | ||
| Q3 24 | $-39.0M | $-68.6M | ||
| Q2 24 | $89.6M | $-79.0M | ||
| Q1 24 | $76.0M | $-193.9M |
| Q4 25 | 39.9% | -48.6% | ||
| Q3 25 | -22.3% | -58.0% | ||
| Q2 25 | 46.6% | -66.5% | ||
| Q1 25 | 20.3% | -120.5% | ||
| Q4 24 | 43.1% | -48.3% | ||
| Q3 24 | -16.3% | -49.2% | ||
| Q2 24 | 39.4% | -53.7% | ||
| Q1 24 | 27.7% | -178.2% |
| Q4 25 | 2.5% | 0.5% | ||
| Q3 25 | 3.7% | 0.8% | ||
| Q2 25 | 3.5% | 1.5% | ||
| Q1 25 | 3.1% | 1.0% | ||
| Q4 24 | 3.3% | 0.1% | ||
| Q3 24 | 4.0% | 1.2% | ||
| Q2 24 | 3.9% | 1.4% | ||
| Q1 24 | 3.3% | 3.0% |
| Q4 25 | 1.50× | — | ||
| Q3 25 | -2.99× | — | ||
| Q2 25 | 2.98× | — | ||
| Q1 25 | 0.94× | — | ||
| Q4 24 | 1.66× | — | ||
| Q3 24 | -0.71× | — | ||
| Q2 24 | 2.83× | — | ||
| Q1 24 | 1.25× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LOPE
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
